United Therapeutics (UTHR) Interest & Investment Income (2009 - 2026)

United Therapeutics has disclosed Interest & Investment Income across 16 years of filings, most recently posting $31.5 million for Q2 2026.

• In Q2 2026, Interest & Investment Income fell 38.6% year-over-year to $31.5 million; the TTM figure through Jun 2026 stood at $162.9 million (down 19.16% YoY), while the FY2025 annual figure was $192.0 million, down 3.57% from the prior year.
• Interest & Investment Income came in at $31.5 million for Q2 2026 at United Therapeutics, down from $41.8 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $53.8 million in Q1 2024 to a low of $4.3 million in Q1 2022.
• Average Interest & Investment Income over 5 years is $37.4 million, with a median of $44.2 million recorded in 2023.
• Year-over-year, Interest & Investment Income jumped 579.07% in 2023 and tumbled 38.6% in 2026.
• Over 5 years, Interest & Investment Income stood at $20.8 million in 2022, then surged by 145.19% to $51.0 million in 2023, then dropped by 3.33% to $49.3 million in 2024, then decreased by 12.37% to $43.2 million in 2025, then declined by 27.08% to $31.5 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $31.5 million in Q2 2026, $41.8 million in Q1 2026, and $43.2 million in Q4 2025.